TheraRadar
Data updated: Jun 28, 2026

ISOPTO CARPINE (pilocarpine hydrochloride) · Novartis

Oncology Approved 2010-06-22

: Pilocarpine hydrochloride tablets, USP are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome.

1
Indication
--
Phase 3 Trials
1
Priority Reviews
16
Years on Market

Details

Status
Prescription
First Approved
2010-06-22
Routes
OPHTHALMIC
Dosage Forms
SOLUTION/DROPS

Companies

Active Ingredient: PILOCARPINE HYDROCHLORIDE

ISOPTO CARPINE Approval History

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
15 FDA actions from 2010 to 2014
Feb 2014 SUPPL Priority
Mfg · Manufacturing (CMC)
Jan 2014 SUPPL Priority
Mfg · Manufacturing (CMC)
Feb 2013 SUPPL Priority
Mfg · Manufacturing (CMC)

What ISOPTO CARPINE Treats

4 indications

ISOPTO CARPINE is approved for 4 conditions since its original approval in 2010. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Dry Mouth
  • Salivary Gland Hypofunction
  • Head and Neck Cancer
  • Sjogren's Syndrome
Source: FDA Label

ISOPTO CARPINE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Indication competitors

2

Same indication, different mechanism — what else might this patient receive?

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to ISOPTO CARPINE

3 of 5

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

PILOCARPINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE
4 shared
FDC LTD
Shared indications:
Dry MouthSalivary Gland HypofunctionHead and Neck Cancer +1 more
SALAGEN
PILOCARPINE HYDROCHLORIDE
4 shared
ADVANZ PHARMA
Shared indications:
Dry MouthSalivary Gland HypofunctionHead and Neck Cancer +1 more
CEVIMELINE HYDROCHLORIDE
CEVIMELINE HYDROCHLORIDE
1 shared
NOVEL LABS INC
Shared indications:
Sjogren's Syndrome
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ISOPTO CARPINE FDA Label Details

Indications & Usage

FDA Label (PDF)

: Pilocarpine hydrochloride tablets, USP are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome.

Track ISOPTO CARPINE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.